rubius
therapeutics
presents
preclinical
data
red
cell
oncology
product
candidate
cancers
demonstrating
dual
mechanism
action
cambridge
globe
newswire
rubius
therapeutics
nasdaq
ruby
biopharmaceutical
company
genetically
engineering
red
blood
cells
create
entirely
new
class
cellular
medicines
called
red
cell
today
announced
presentation
new
preclinical
data
supporting
lead
artificial
cell
aapc
program
potential
treatment
human
papillomavirus
hpv
cancers
data
presented
today
federation
clinical
immunology
societies
focis
virtual
annual
meeting
earlier
month
american
association
cancer
research
aacr
tumor
immunology
conference
preclinical
data
demonstrate
first
time
dual
mechanism
action
functioning
cell
boost
hpv
cell
responses
also
promoting
broad
immune
system
stimulation
innate
adaptive
immunity
said
laurence
turka
chief
scientific
officer
rubius
therapeutics
ability
engage
arms
immune
system
expected
provide
robust
response
cells
natural
killer
cells
making
harder
tumor
escape
immune
evasion
dual
mechanism
action
key
part
development
epitope
spreading
meaning
may
induce
expansion
immune
response
secondary
epitopes
antigens
expressed
well
development
potent
memory
response
potentially
enabling
body
remember
cancer
identity
critical
providing
protection
recurrence
data
summaries
focis
virtual
annual
meeting
engineered
allogeneic
artificial
red
cell
therapeutic
promotes
cell
expansion
activity
poster
allogeneic
aapc
therapy
product
candidate
engineered
induce
immune
response
expanding
cells
expresses
hundreds
thousands
copies
hpv
peptide
antigen
bound
major
histocompatibility
complex
mhc
class
proteins
costimulatory
molecule
cytokine
cell
surface
mimic
human
interactions
rubius
therapeutics
demonstrated
dual
mechanism
action
mouse
surrogates
function
aapc
boost
hpv
responses
promote
hpv
stimulation
innate
nk
cells
adaptive
immune
cells
responses
mouse
surrogates
promote
tumor
control
memory
formation
epitope
spreading
tumor
models
vivo
treatment
mouse
surrogate
results
minimal
reversible
effects
vivo
body
weight
change
ifnγ
alt
levels
likely
due
biodistribution
vasculature
spleen
aacr
tumor
immunology
immunotherapy
conference
allogeneic
red
blood
artificial
antigen
presenting
cell
expressing
mhc
peptide
engages
primary
human
cells
boosts
general
immune
responses
poster
functions
aapc
boost
hpv
cells
vitro
selectively
expands
cells
induces
activation
effector
phenotype
function
tbet
granzyme
b
cells
presence
hpv
cells
increases
secretion
interferon
gamma
ifnγ
presence
hpv
cells
compared
peripheral
blood
mononuclear
cells
pbmcs
alone
promotes
hpv
adaptive
innate
immune
responses
vitro
upregulation
observed
specific
cells
expands
nk
cells
increases
activation
effector
upregulation
granzyme
b
nk
cells
increases
secretion
ifnγ
pbmcs
alone
taken
together
findings
support
potential
effective
therapy
treatment
hpv
cancers
hpv
positive
cancers
human
papillomavirus
hpv
associated
approximately
percent
cervical
cancers
approximately
percent
head
neck
squamous
cell
carcinoma
hnscc
arising
oropharynx
approximately
percent
hnscc
arising
locations
approximately
percent
anal
cancers
despite
available
therapies
critical
need
remains
new
treatment
options
advanced
hpv
cancers
allogeneic
aapc
therapy
product
candidate
engineered
induce
immune
response
expanding
cells
expresses
hundreds
thousands
copies
hpv
peptide
antigen
bound
major
histocompatibility
complex
mhc
class
proteins
costimulatory
molecule
cytokine
cell
surface
mimic
human
interactions
rubius
therapeutics
rubius
therapeutics
biopharmaceutical
company
developing
new
class
medicines
called
red
cell
company
proprietary
red
designed
genetically
engineer
culture
red
cell
selective
potent
allogeneic
cellular
therapies
potential
treatment
several
diseases
across
multiple
therapeutic
areas
rubius
initial
focus
advance
product
candidates
treatment
cancer
autoimmune
diseases
leveraging
two
distinct
therapeutic
modalities
potent
interaction
tolerance
induction
rubius
therapeutics
manufacturing
site
recently
named
top
best
places
work
rhode
island
among
companies
providence
business
news
information
visit
follow
us
twitter
linkedin
like
us
facebook
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
expectations
regarding
therapeutic
potential
red
cell
therapeutics
including
treatment
hpv
tumors
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
uncertainties
related
development
red
cell
therapeutic
product
candidates
therapeutic
potential
risks
identified
sec
filings
including
quarterly
report
form
quarter
ended
june
subsequent
filings
sec
risks
uncertainties
related
severity
duration
impact
business
operations
caution
place
undue
reliance
statements
speak
date
made
disclaim
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
views
date
hereof
relied
upon
representing
views
subsequent
date
explicitly
disclaim
obligation
update
statements
contacts
investors
lori
melançon
vice
president
corporate
communications
investor
relations
media
marissa
hanify
director
corporate
communications
dan
budwick
dan
